Literature DB >> 28017532

Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.

Ina Terstiege1, Matthew Perry2, Jens Petersen3, Christian Tyrchan2, Tor Svensson2, Helena Lindmark3, Linda Öster3.   

Abstract

A novel class of potent PI3Kδ inhibitors with >1000-fold selectivity against other class I PI3K isoforms is described. Optimization of the substituents on a triazole aminopyrazine scaffold, emerging from an in-house PI3Kα program, turned moderately selective PI3Kδ compounds into highly potent and selective PI3Kδ inhibitors. These efforts resulted in a series of aminopyrazines with PI3Kδ IC50⩽1nM in the enzyme assay, some of the most selective PI3Kδ inhibitors published to date, with a cell potency in a JeKo-cell assay of 20-120nM.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aminopyrazine; Inflammation; PI3Kδ inhibitor; Phosphoinositide 3-kinase

Mesh:

Substances:

Year:  2016        PMID: 28017532     DOI: 10.1016/j.bmcl.2016.11.004

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

Authors:  Klemens Hoegenauer; Nicolas Soldermann; Frédéric Zécri; Ross S Strang; Nadege Graveleau; Romain M Wolf; Nigel G Cooke; Alexander B Smith; Gregory J Hollingworth; Joachim Blanz; Sascha Gutmann; Gabriele Rummel; Amanda Littlewood-Evans; Christoph Burkhart
Journal:  ACS Med Chem Lett       Date:  2017-08-25       Impact factor: 4.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.